Holen Sie sich die Stockscreener-App
6.24
2.19%
-0.14
Schlusskurs vom Vortag:
$6.38
Offen:
$6.35
24-Stunden-Volumen:
596.28K
Relative Volume:
0.58
Marktkapitalisierung:
$375.25M
Einnahmen:
$217.78M
Nettoeinkommen (Verlust:
$-239.55M
KGV:
-1.541
EPS:
-4.0492
Netto-Cashflow:
$-127.30M
1W Leistung:
+0.48%
1M Leistung:
+3.48%
6M Leistung:
-14.87%
1J Leistung:
+25.05%
1-Tages-Spanne:
$6.145
$6.355
1-Wochen-Bereich:
$6.145
$6.615
52-Wochen-Spanne:
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.24 | 375.25M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Truist | Buy |
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Vanda Pharmaceuticals plans fireside chat at Boston investor summit - Stock Titan
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - PR Newswire
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation - Investing.com India
Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S - AllSci
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S - Quantisnow
Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market - ad-hoc-news.de
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
VNDAVanda Pharmaceuticals Inc Volatility & Greeks - Finviz
McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY® - McDermott Will & Schulte
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA) - Yahoo Finance
Vanda Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- McGuire Daniel Patrick - Moomoo
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2026 Past Winners - WTA Tennis
Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group - WTA Tennis
Watch Vit Kopriva vs Ignacio Buse - tod.tv
Price to book forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – FWB:VM4 - TradingView
Price to earnings forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3 - TradingView
Enterprise value to EBIT forward of Vanda Pharmaceuticals Inc. – FWB:VM4 - TradingView
Price to earnings forward of Vanda Pharmaceuticals Inc. – FWB:VM4 - TradingView
Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Net current asset value per share of Vanda Pharmaceuticals Inc. – LSX:A0JJT3 - TradingView
Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3 - TradingView
Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda - Barchart.com
Athletics announces jersey patch partnership with biopharmaceutical company - The GW Hatchet
Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA) - TradingView
VNDA Forecast — Price Target — Prediction for 2027 - TradingView
Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner - George Washington University Athletics
Watch VANDA Pharmaceuticals Berlin Tennis Open (Quarterfinals) | Disney+ - Disney Plus
Licensable picture: VANDA Pharmaceuticals Berlin Tennis Open 2026 - reutersconnect.com
VNDA|Vanda Pharmaceuticals Inc|Price:6.000|Chg%:0.20 - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):